NewslettersPulmonary Cell NewsTrial Results for New Lung Cancer Drug Are ‘Off the Charts’, Say DoctorsBy Noshin Noorjahan - June 6, 20240221More than half of patients with advanced forms of lung cancer who took lorlatinib were still alive after five years with no progression.[The Guardian]Press Release